Could stopping acid reflux drugs improve IBD treatment?

NCT ID NCT07691138

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study explores whether people with inactive inflammatory bowel disease (IBD) can safely stop taking proton pump inhibitors (PPIs), a common acid-reducing medication. Evidence suggests PPIs may make IBD treatments less effective and increase hospital visits. The trial will recruit 80 participants aged 16 and older with stable IBD who have been on PPIs for over six months, randomly assigning half to stop the medication. Researchers will measure how many can successfully stop, how well they adhere, and whether IBD symptoms change over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Proton pump inhibitor (PPI) withdrawal
What this could lead to
If successful, this could show that stopping PPIs is safe and may improve how well IBD medications work, reducing the need for hospital care.
What could go wrong
This is a small feasibility study, not a large trial. Some people may experience a short-term increase in acid reflux after stopping PPIs, and it is unclear how many can stay off them long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Nottingham

    RECRUITING

    Nottingham, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.